- Home
- RPT vs NOTV Comparison
RPT vs NOTV Comparison
Compare RPT & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPT
- NOTV
- Stock Information
- Founded
- RPT 2014
- NOTV 1974
- Country
- RPT United States
- NOTV United States
- Employees
- RPT N/A
- NOTV N/A
- Industry
- RPT
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- RPT
- NOTV Health Care
- Exchange
- RPT NYSE
- NOTV Nasdaq
- Market Cap
- RPT 124.1M
- NOTV 137.5M
- IPO Year
- RPT N/A
- NOTV 1997
- Fundamental
- Price
- RPT $2.75
- NOTV $2.60
- Analyst Decision
- RPT Strong Buy
- NOTV Strong Buy
- Analyst Count
- RPT 1
- NOTV 1
- Target Price
- RPT $4.00
- NOTV $5.00
- AVG Volume (30 Days)
- RPT 112.3K
- NOTV 598.2K
- Earning Date
- RPT 04-28-2025
- NOTV 05-07-2025
- Dividend Yield
- RPT 8.79%
- NOTV N/A
- EPS Growth
- RPT N/A
- NOTV N/A
- EPS
- RPT N/A
- NOTV N/A
- Revenue
- RPT N/A
- NOTV $480,402,000.00
- Revenue This Year
- RPT N/A
- NOTV $5.57
- Revenue Next Year
- RPT $19.21
- NOTV $5.23
- P/E Ratio
- RPT N/A
- NOTV N/A
- Revenue Growth
- RPT N/A
- NOTV N/A
- 52 Week Low
- RPT $2.29
- NOTV $1.15
- 52 Week High
- RPT $3.86
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- RPT N/A
- NOTV 58.71
- Support Level
- RPT N/A
- NOTV $1.96
- Resistance Level
- RPT N/A
- NOTV $2.96
- Average True Range (ATR)
- RPT 0.00
- NOTV 0.24
- MACD
- RPT 0.00
- NOTV 0.08
- Stochastic Oscillator
- RPT 0.00
- NOTV 64.00
About RPT RITHM PROPERTY TRUST INC
Rithm Property Trust Inc is a real estate investment trust (REIT) externally managed by an affiliate of Rithm Capital Corp. (Rithm). The group is embarking on a new commercial real estate-focused investment. Its tailored approach to investment management seeks to generate attractive risk-adjusted returns for stockholders over the long term through dividends and capital appreciation.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.